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Neuronal cell deathOur previous study showed that the environmental neurotoxicant non-dioxin-like polychlorinated
biphenyl (PCB)-95 increases RE1-silencing transcription factor (REST) expression, which is related to
necrosis, but not apoptosis, of neurons. Meanwhile, necroptosis is a type of a programmed necrosis that
is positively regulated by receptor interacting protein kinase 1 (RIPK1), RIPK3 and mixed lineage kinase
domain-like (MLKL) and negatively regulated by caspase-8. Here we evaluated whether necroptosis con-
tributes to PCB-95-induced neuronal death through REST up-regulation. Our results demonstrated that in
cortical neurons PCB-95 increased RIPK1, RIPK3, and MLKL expression and decreased caspase-8 at the
gene and protein level. Furthermore, the RIPK1 inhibitor necrostatin-1 or siRNA-mediated RIPK1,
RIPK3 and MLKL expression knockdown significantly reduced PCB-95-induced neuronal death.
Intriguingly, PCB-95-induced increases in RIPK1, RIPK3, MLKL expression and decreases in caspase-8
expression were reversed by knockdown of REST expression with a REST-specific siRNA (siREST).
Notably, in silico analysis of the rat genome identified a REST consensus sequence in the caspase-8 gene
promoter (Casp8-RE1), but not the RIPK1, RIPK3 and MLKL promoters. Interestingly, in PCB-95-treated
neurons, REST binding to the Casp8-RE1 sequence increased in parallel with a reduction in its promoter
activity, whereas under the same experimental conditions, transfection of siREST or mutation of the
Casp8-RE1 sequence blocked PCB-95-induced caspase-8 reduction. Since RIPK1, RIPK3 and MLKL rat
genes showed no putative REST binding site, we assessed whether the transcription factor cAMP
Responsive Element Binding Protein (CREB), which has a consensus sequence in all three genes, affected
neuronal death. In neurons treated with PCB-95, CREB protein expression decreased in parallel with a
reduction in binding to the RIPK1, RIPK3 and MLKL gene promoter sequence. Furthermore, CREB overex-
pression was associated with reduced promoter activity of the RIPK1, RIPK3 and MLKL genes. Collectively,
these results indicate that PCB-95 was associated with REST-induced necroptotic cell death by increasing
RIPK1, RIPK3 and MLKL expression and reducing caspase-8 levels. In addition, since REST is involved in
several neurological disorders, therapies that block REST-induced necroptosis could be a new strategy
to revert the neurodetrimental effects associated to its overexpression.
 2017 Elsevier Inc. All rights reserved.1. Introduction
Polychlorinated Biphenyls (PCBs) are organic pollutants (POPs)
that persist in the environment and bioaccumulate through the food
chain [1]. These toxic compounds were produced and used commer-
cially in industrial manufacturing between the 1930s and 1970s.
Although PCBs were banned in the late 1970s and early 1980s [2],
these compounds can still be found in the fatty tissues of fish and
marine mammals [3]. Interestingly, PCB exposure can be correlated
with the development of neurological disorders, such as Alzheimer’s
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sclerosis (ALS) [6]. PCBscanbedivided into twomajor groups:dioxin-
like (DL),whichhave a coplanar structure, andnon-dioxin-like (NDL),
which adopt a non-coplanar structure [7]. In vitro experiments
showed that both DL-and NDL-PCBs can induce apoptotic and necro-
tic neuronal cell death [8–10]. We previously demonstrated that the
PCB mixtures Aroclor-1254 and NDL-PCB-95 both caused necrotic,
but not apoptotic, neuronal death by increasing expression levels of
the repressor element 1 (RE1)-silencing transcription factor (REST)
[11,12]. REST represses its target genes by binding to a DNA sequence
motif named the RE1 element and REST dysregulation has been asso-
ciatedwithAlzheimer’s, Parkinson’s,Huntington’s andNiemann-Pick
type C diseases, as well as with epilepsy [13]. Furthermore, increased
expression of REST, with a consequent decrease in expression of tar-
get genes, such as AMPA receptor (AMPAR) GluR2 subunit,mu opioid
receptor 1 (MOR-1), miR132, cocaine- and amphetamine-regulated
transcript (CART), andNa+/Ca2+ exchanger 1 (NCX1), causedneuronal
death [11,12,14,15].More recently, a newtypeof programmednecro-
sis called necroptosis, has been reported [13]. Necroptosis is involved
in several neurological diseases characterized by inflammation,
including stroke,multiple sclerosis (MS), and ALS [16–18]. Activation
of necroptosis is associated with the loss of membrane integrity,
release of damage-associated molecular pattern molecules (DAMPs)
and subsequent cell death [19]. Several molecular mechanisms are
involved in necroptosis: (1) necroptosis stimulated when cells are
deficient in caspase-8, or in the presence of a caspase inhibitor [20];
(2) activationof receptor interactingprotein kinase1 (RIPK1)asa crit-
ical upstream step event in necroptosis; (3) RIPK1 binding to RIPK3 to
activate MLKL that is recruited to the plasma membrane, where it
promotespore formationandconsequent cell lysis [20]. Interestingly,
necroptosis can be pharmacologically reduced by the RIPK1 inhibitor
necrostatin-1 (Nec-1) or its derivatives, and by the MLKL inhibitor
necrosulfonamide (NSA) [21]. Since treatment with 8 lM PCB-95
for 24 h could induce necrotic neuronal death in a caspase-
independent manner [11] that involved REST, in this studywe inves-
tigated whether necroptosis is implicated in the neurotoxic effect of
PCB-95 by examining whether Nec-1 can modulate PCB-95-
induced cell death and if PCB-95 treatment affects REST-mediated
regulation of gene and protein expression of RIPK1, RIPK3, MLKL
and caspase-8.2. Material and methods
2.1. Materials
The compound 2,3,6-20,50-pentachlorinated biphenyl (PCB-95)
(cod: RPC-130AS) (stock solution 305 lM) was purchased from
Ultra Scientific (North Kingstown, RI, USA). Culture media and sera
were purchased from Invitrogen (Milan, Italy). The RIPK1-inhibitor
5-(Indol-3-ylmethyl)-3-methyl-2-thio-Hydantoin, Necrostatin-1
(Nec-1) was purchased from Sigma (Milan, Italy) (cod. N9037;
stock solution 20mM), For those requiring dilution in Dimethyl sul-
foxide (DMSO), the final DMSO concentration was 0.1% that did not
induce cellular toxicity. All restriction enzymes, DNA-modifying
enzymes and Luciferase reporter kits were purchased from Pro-
mega Italy. Synthetic oligonucleotides were from Eurofins Geno-
mics. All siRNAs used were purchased from Quiagen Italy. siRNAs
for RIPK1 (siRIPK1) (SI01685873), RIPK3 (siRIPK3) (SI02026409),
MLKL (siMLKL) (SI03308753), whereas for REST (siREST) and nega-
tive control (siCTL) have been already published [22].2.2. Cell Cultures and drug treatment
SH-SY5Y human neuroblastoma cells at passages 15–20 and
cortical neurons (DIV 7–9) from rat embryos were prepared aspreviously reported [22,23]. All the experiments on primary corti-
cal neurons were performed according to the procedures described
in experimental protocols approved by the Ethics Committee of the
‘Federico II’ University of Naples. PCB-95 treatment was performed
in low serum. For Nec-1 experiments neurons were pre-treated for
2 h with the drug at 1, 5, 10 and 20 mM followed with PCB-95 8 mM
for 24 h. The plates used and the density of cells plated have been
previously published [22].
2.3. Cloning of the caspase-8, RIPK1, RIPK3 and MLKL promoter
regions
Approximately 1-Kb fragments, including the putative rat
caspase-8, RIPK1, RIPK3 and MLKL promoter sequences were found
by Genomatix software (http://genomatix.de). Amplification of
these promoter regions was performed using PrimeSTAR GLX Pfu
DNA polymerase (cod: R050A: Takara) on rat genomic DNA.
Caspase-8 amplicon primers from base 1216 (5-CAAATGCACA
GAACAGCTGATTATACC-3) to base +15 (5-CGCCCGCCAGTTC
TTAAGG-3) of exon 1 (Ensembl association number:
ENSRNOE00000313891). RIPK1 amplicon primers from base
824 (5-CTGTGAATGTTTGGGATTTGGAGG-3) to base +22 (5-
CGGTCCCCAGCTCTGAAA-3) of exon 1 (Ensembl association num-
ber ENSRNOE00000455609). RIPK3 amplicon primers from base
1387 (5-CTTTTCTGAGACAGGAAGCACGG-3) to base +18 (5-
GGCTCAGCTTGGGTCTCTG-3) of exon 1 (Ensembl association num-
ber ENSRNOE00000199113). MLKL amplicon primers from base
1174 (5-GCTGGAGAGATGGCTTAGTGG-3) to base +26 (5-GAT
GATCTGTCCCAATTTATCCATACC-3) of exon 1 (Ensembl association
number ENSRNOE00000223514). The amplified fragments were
cloned in the pSC-B vector using the StrataClone Blunt PCR Cloning
Kit (cod: 240207, Agilent Technologies, USA) and their identities
were confirmed by DNA sequence analysis. The Caspase-8, RIPK1,
RIPK3 and MLKL fragments containing the putative promoter
regions were subcloned upstream of the firefly luciferase open
reading frame in the pGL3basic vector by using Not1 and Xho1
restriction enzymes. These new constructs were named pGL3-
casp8, pGL3-RIPK1, pGL3-RIPK3 and pGL3-MLKL. Presumed REST
binding site on Caspase-8 promoter and presumed CREB binding
sites on RIPK1, RIPK3 and MLKL promoters were predicted by using
Jaspar database [24]. Mutagenesis of REST binding site on Caspase-
8 and CREB binding sites on RIPK1, RIPK3 and MLKL was performed
by Quik Change Site-Directed Mutagenesis Kit (cod:200518, Strata-
gene, USA) to obtain the following constructs: (1) pGL3-casp8-
RE1mut (GTGCTGTCCAGGGTGCTGT), (2) pGL3-RIPK1-CRE-mut
(GTGTATTTGACATCAAATT), (3) pGL3-RIPK3-CRE-mut (TTTCTG
GTGAGGTACATTTTC) and (4) pGL3-MLKL-CRE-mut (TCTGTAAT-
GAGGTCTGATGCC), in which underlined bases represent mutated
sequences.
2.4. Small Interfering RNAs (siRNAs), constructs transfections
siRNAs and constructs transfections in neurons were performed
24 h before PCB-95 exposure with Lipofectamine LTX (15338–100,
Invitrogen, Milan, Italy), in accordance with the manufacturer’s
protocol, as previously reported [11]. Specifically, siRIPK1, siRIPK3
and siMLKL were transfected at the concentration of 50nM,
whereas siREST and siCTL as previously published [11]. For CREB
overexpression, cortical neurons were transfected with 15 mg of
construct RSV CREB, that was a gift from Marc Montminy (Plasmid
# 22394 Addgene, Teddington, UK) [25], or with the empty vector
pRC/RSV (Mock). For ChIP assay experiments on exogenous chro-
matin in SH-SY5Y, cells were transiently transfected, as previously
described [22], with the following constructs:pGL3-casp8 or pGL3-
casp8-RE1mut, pGL3-RIPK1 or pGL3-RIPK1-CREmut, pGL3-RIPK3
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After 6 h of incubation with transfection mix the medium was
changed with DMEM containing PCB-95 8 mM and left for 24 h.
Transfection efficiency was approximately of about 45% for SH-
SY5Y cells and 35% for cortical neurons (data not shown).
2.5. Luciferase assay experiments
To study the Caspase-8, RIPK1, RIPK3 and MLKL promoter activ-
ities, cortical neurons were co-transfected with 1,5 mg of total DNA
constructs, including 800 ng of reporter vectors, that are: for
Caspase-8 experiments (1) pGL3basic, (2) pGL3-casp8, (3) pGL3-
casp8-RE1mut; for RIPK1 experiments: (1) pGL3basic, (2) pGL3-
RIPK1, (3) pGL3-RIPK1-CREmut; for RIPK3 experiments: (1)
pGL3basic, (2) pGL3-RIPK3, (3) pGL3-RIPK3-CREmut; for MLKL
experiments: (1) pGL3basic, (2) pGL3-MLKL, (3) pGL3-MLKL-
CREmut. For siRNAs transfection, 50 nM of siCTL or siREST was
used. To overexpress CREB, we co-transfected 500 ng of CREB con-
struct or empty vector. In all luciferase experiments each transfec-
tion mix contained 200 ng of the pRL-TK vector expressing the
renilla luciferase gene, that provides an internal control value to
which expression of the firefly luciferase reporter gene has been
normalized. After 2 h of incubation with transfection mix the med-
ium was replaced with a fresh one containing PCB-95 (8 mM) and
analyzed after 24 h with the Dual-Luciferase Reporter Assay Sys-
tem kit (E1910) (Promega Italy). Luciferase activity was expressed
as firefly-to-renilla ratio.
2.6. qRT-PCR analysis
First-strand cDNA, qRT-PCR and data analysis were performed
as previously published [26]. qRT-PCR was performed in a 7500
Fast real-time PCR system. Protocol for the amplification was pre-
viously described [27]. The data were normalized by hypoxanthine
phosphoribosyl-transferase (HPRT) as an internal control. Differ-
ences in mRNA content between groups were calculated as nor-
malized values by using 2DDct formula. The oligonucleotide
sequences were: for Caspase-8 (FW 50-GATCATGGACTGGGACGAGT
TAA-30 2376–2398 and RV 50-CCAGAATCGCATGCAGACAA-30 2436–
2417) (GenBank accession number XM_008767135.2), for RIPK1
(FW 50-GCATGACTGTGTGCCCTTACC-30 1324–1344 and RV 50-CAGC
GAACCGGGTTGTTCT-30 1381–1363) (GenBank accession number
NM_001107350.1), for RIPK3 (FW 50-CAAAAAGGTACAGAGGTG
GATTGC-30 1425–1486 and RV 50-GGCGGTCCAGCATTTCAT-30
1466–1483) (GenBank accession number NM_139342.1), for MLKL
(FW 50-AATGCTCACTAAAACCCATGCA-30 871–892 and RV 50-CCTT
CGGAATCTCCTTGACTTG-30 912–933) (GenBank accession number
XM_008772570.2) and for CREB (FW 50-TTGCCACATTAGCCCAGG
TAT-30 353–373 and RV 50-ACCTGGACTGTCTGCCCATT-30 433–
452) (GenBank accession number XM_017596652.1). Data are
obtained from three independent experiments.
2.7. Western blotting analysis and immunoprecipitation
Neurons were collected in ice-cold lysis buffer[28] containing
anti-protease mixture (P8340 Sigma). Loaded proteins were
200 mg for Caspase-8, 120 mg for RIPK1 and 50 mg for RIPK3 and
MLKL, and all were separated on 8% SDS polyacrylamide gels. CREB
(60 mg) was separated on 10% SDS polyacrylamide gels. Immuno-
precipitation of MLKL was performed as previously described
[28]. The precipitated samples were then subjected toWestern blot
analysis as previously described [11,28]. The membranes were
incubated overnight at 4 C in the blocking buffer with polyclonal
antibodies against REST [29], Caspase-8 (sc-6136, Santa Cruz
Biotechnology, CA, USA), RIPK1 (sc-41169, Santa Cruz Biotechnol-
ogy), RIPK3 (sc-135170, Santa Cruz Biotechnology), and MLKL(orb229539, Biorbyt, Cambridge, UK) at 1:500 dilution, 1:1000
monoclonal antibody for CREB (sc-271 Santa Cruz Biotechnology)
and for b-Actin (A4700 Sigma) and 1:5000 monoclonal antibody
for Tubulin (T5168 Sigma). In all the experiments the optical den-
sity of the bands was normalized to b-Actin or Tubulin. Data are
obtained from three independent experiments.
2.8. Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed with cortical neurons with or with-
out PCB-95 and by using 3 mg of antibody for REST [22] or for CREB
and polyclonal IgG as negative control [22]. Two-microliter ali-
quots of immunoprecipitated DNA (in duplicate for each treatment
group) were amplified by PCR with Fast SYBR green master mix
(Applied Biosystems) in a 7500 Fast real-time PCR system Protocol.
The primers used for amplification of immunoprecipitated DNA
were for Caspase-8:FW 50-TTCCAGACCGAGACCCAGAA-3 (ChIP-
casp8), RV 50-TGAGCAATTAAAGAACAGGGTCAA-30; for RIPK1: FW
50-TTGGAGGCTTTTTATGTGTATTTGAC-30 (ChIP-RIPK1), RV 50-T
CGGTCCCCAGCTCTGAAA-30; for RIPK3: FW 50-TTGGCTTGTTTTTCC
TTTGTTTG-30 (ChIP-RIPK3), RV 50-CTCACCAGAAAGGGAGAAA
TATCC-30; and for MLKL: FW 50-AATGAGGTCTGATGCCCTCTTC-30
(ChIP-MLKL), RV 50-GCATCCTTTCAATTTCTGTGACTTT-30. Results
obtained from three different PCR experiments were expressed as
a percentage of the control, all normalized for the DNA input.
2.9. Transient transfection ChIP
For the transient ChIP assay, SH-SY5Y cells at 50% of confluence
were transfected for Caspase-8 experiments with: (1) pGL3-casp8,
(2) pGL3-casp8-RE1mut; for RIPK1 experiments with: (1) pGL3-
RIPK1, (2) pGL3-RIPK1-CREmut; for RIPK3 experiments with: (1)
pGL3-RIPK3, (2) pGL3-RIPK3-CREmut; for MLKL experiments with:
(1) pGL3-MLKL1, (2) pGL3-MLKL-CREmut. 24 h after transfection,
cells were exposed to PCB-95 (8 mM/24 h). Transfection conditions
and ChIP assay have been performed as described above. Antibod-
ies used in the procedure include anti-REST, anti-CREB, and poly-
clonal IgG as negative control. Exogenous DNA containing: (1)
pGL3-casp8 or the mutated pGL3-casp8-RE1mut was amplified
using as forward primer ChIP-casp8; (2) pGL3-RIPK1 or the
mutated pGL3-RIPK1-CREmut was amplified using as forward pri-
mer ChIP-RIPK1; (3) pGL3-RIPK3 or the mutated pGL3-RIPK3-
CREmut was amplified using as forward primer ChIP-RIPK3; (4)
pGL3-MLKL or the mutated pGL3-MLKL-CREmut was amplified
using as forward primer ChIP-MLKL. For all PCR experiments of
transient transfection ChIP assay LucNrev was used as reverse pri-
mer [22]. Results were expressed as the percentage of the pGL3-
casp8 or pGL3-RIPK1 or pGL3-RIPK3 or pGL3-MLKL and all were
normalized to their respective DNA input. Results obtained from
three different PCR experiments were expressed as a percentage
of the control, all normalized for the DNA input.
2.10. Determination of cell death
Cell injury was assessed with the lactate dehydrogenase (LDH)
cytotoxicity kit from Cayman, as previously reported [14].Cortical
neurons had been treated with PCB-95 8 mM for 24 h alone or after:
(1) 2 h pretreatment with Nec-1 at 1, 5, 10 and 20 mM, or (2) trans-
fection with siCTL, siRIPK1, siRIPK3 and siMLKL. Neurons treated
with 1% Triton X-100 (Sigma) was considered 100% of cell death.
Data are obtained from three independent experiments.
2.11. Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was per-
formed with GraphPad Prism 5.0 (La Jolla, CA, USA). For the analy-
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ANOVA with Tukey’s post hoc test was used, whereas for the anal-
ysis between two experimental groups unpaired Student’s t test
was used. ⁄P  0.05 was considered statistically significant.3. Results
3.1. PCB-95 induces an increase in RIPK1, RIPK3 and MLKL expression
and interaction in cortical neurons
Exposure to 8 lM PCB-95 for 12 and 24 h induced a significant
increase in the mRNA and protein expression of the positive regu-
lators of necroptosis RIPK1, RIPK3 and MLKL, whereas that of the
negative regulator of necroptosis [16] caspase-8 was reduced com-
pared to the control (Fig. 1A–E). Since RIPK1-RIPK3-MLKL form a
complex termed the necrosome, which is a marker of cell death
[30], we investigated RIPK1-RIPK3-MLKL interactions in neurons
exposed to PCB-95. Immunoprecipitation of neuronal cell lysates
with an anti-MLKL antibody demonstrated an increase in RIPK1-
RIPK3-MLKL interactions after PCB-95 exposure, relative to control
neurons (Fig. 1F). Together these results indicated that PCB-95
exposure can affect levels and interactions of proteins involved in
necrosome formation.
3.2. Nec-1 treatment or RIPK1, RIPK3 and MLKL knocking-down
reduce PCB-95-induced cell death
LDH assays indicated that neuronal survival significantly
improved in a dose-dependent manner when neurons were pre-
treated with increasing amounts of Nec-1 (1, 5, 10 and 20 lM),
as compared to cells exposed to PCB-95 alone. Nec-1 yielded max-
imum neuroprotection at 10 lM (Fig. 2A). To evaluate the role of
RIPK1, RIPK3 and MLKL in modulating PCB-95-induced cell death,
neurons were transfected with siRIPK1, siRIPK3 and siMLKL, which
reduced protein expression by 42%, 39%, and 37%, respectively,
compared to transfection with non-specific control siRNA, siCTL
(Fig. 2B–D). Importantly, as revealed by LDH release, PCB-95-
induced neuronal death was significantly reduced following RIPK1,
RIPK3 and MLKL expression knockdown (Fig. 2E).
3.3. REST knockdown prevents RIPK1, RIPK3, MLKL up-regulation and
caspase-8 down-regulation in neurons exposed to PCB-95
Because REST is involved in PCB-95 induced neuronal death
mechanisms [11], we evaluated the effect of siREST transfection
on RIPK1, RIPK3, MLKL and caspase-8 expression in PCB-95-
treated neurons. siREST efficiency to reduce REST protein expres-
sion was already published [11].
Notably, siREST transfection significantly blocked PCB-95-
mediated increases in RIPK1, RIPK3, MLKL gene and protein
expression (Fig. 3A–C, E–G), and reverted PCB-95-dependent
reductions in caspase-8 gene and protein expression (Fig. 3D, H).
Together these results suggest that REST has a role in necroptosis
regulated by the RIPK1-RIPK3-MLKL-Casp8 pathway.
3.4. PCB-95 reduces caspase-8 promoter activity by binding to a
specific RE1 sequence
By a search of the Jaspar database [31] (www.jaspar.genereg.
net) with a search threshold score of 90.0, we found an RE1 ele-
ment in the genomic region upstream of rat caspase-8-coding
sequence (ENSRNOE00000313891), named Casp8-RE1, that was
located on the forward DNA strand from nucleotides 1153 to
1134 relative to the transcription start site (TSS) (Fig. 4A, B). ChIP
analysis demonstrated that REST binding to the caspase-8promoter significantly increased after PCB-95 exposure (Fig. 4C).
To corroborate the specific action of REST on the caspase-8 gene,
we generated two reporter vectors containing the caspase-8 pro-
moter region (1216/+15): the first carried the wild type rat
Casp8-RE1 site (pGL3-casp8) and the second had a mutation in
the RE1 element (pGL3-casp8-RE1mut). Transfection of these vec-
tors in neurons demonstrated that PCB-95-mediated decreases in
pGL3-casp8 promoter activity were completely blocked when cells
were transfected with the pGL3-casp8-RE1mut construct or by siR-
EST transfection (Fig. 4D). To confirm that REST binds the Casp8-
RE1 sequence, SH-SY5Y cells were transfected with pGL3-casp8
or pGL3-casp8-RE1mut and treated or not with PCB-95. As
expected, exposure of cells to 8 mM PCB-95 for 24 h increased REST
expression in SH-SY5Y cells. Meanwhile, PCB-95 treatment
increased REST binding to caspase-8 exogenous promoter
sequences in cells transfected with the pGL3-casp8 construct com-
pared to untreated neurons (Fig. 4E), whereas cells transfected
with pGL3-casp8-RE1mut had diminished REST binding to exoge-
nous caspase-8 promoter sequence compared with cells trans-
fected with pGL3-casp8 in the presence of PCB-95.
3.5. PCB-95 induces REST-dependent reductions in CREB to increase
RIPK1, RIPK3 and MLKL mRNA and protein expression
Since a Jaspar search (threshold score of 90.0) showed no RE1
sites in the genomic regions upstream of the coding sequences for
RIPK1 (ENSRNOE00000455609), RIPK3 (ENSRNOE00000199113)
andMLKL genes (ENSRNOE00000223514), and because PCB-95 reg-
ulates the transcription factor CREB expression in neurons [32], we
searched for potential CRE sites in the above-mentioned genomic
regions. Interestingly, one putative CREB binding sequence in each
of the genomic regions upstream of the RIPK1, RIPK3, and MLKL
gene coding sequences was identified (Fig. 5A–D), indicating that
transcription of these genes may be directly regulated by CREB.
We named these sequences RIPK1-CRE, RIPK3-CRE and MLKL-CRE,
which are located on the forward DNA strand from nucleotides
792 to 771, 1013 to 992 and 1081 to 1060, respectively,
relative to the transcription start site (TSS).
Jaspar database searches (threshold score of 90.0) of genomic
regions upstream of the coding sequences of CREB in the rat gen-
ome (ENSRNT00000018326.5; Chr 9: 71228108–71230488
(2000 to +350) were analyzed to identify a putative RE1 site.
Notably, no REST binding site was found (data not shown). Next,
we evaluated the effect of siREST on CREB expression in PCB-95-
treated cells. As shown in Fig. 6A, B, siREST transfection signifi-
cantly reverted PCB-95-reduced CREB protein expression, whereas
CREB mRNA levels were unaffected by either PCB-95 exposure
alone or in combination with siREST. Therefore, to characterize
how CREB determines increases in RIPK1, RIPK3 and MLKL gene
and protein expression following PCB-95 exposure, PCB-95-
treated neurons were transfected with a construct to overexpress
CREB, which increased CREB protein levels by 63% (Fig. 6C). Inter-
estingly, CREB overexpression significantly reverted PCB-95-
mediated increases in RIPK1, RIPK3 and MLKL mRNA and protein
expression (Fig. 6D–I).
3.6. PCB-95 decreases CREB binding to RIPK1, RIPK3 and MLKL
promoter sequences resulting in increased promoter activity
PCB-95-treated neurons had significantly reduced CREB binding
to RIPK1-CRE, RIPK3-CRE and MLKL-CRE sites compared to control
cells (Fig. 7A, D, G). To study the role of PCB-95-mediated reduc-
tions in CREB expression to modulate RIPK1, RIPK3 and MLKL tran-
scription, we inserted a 1.000 bp DNA fragment upstream of the
putative TSS for RIPK1, RIPK3 and MLKL genes carried in pGL3-
based vectors to generate three reporter constructs for luciferase
Fig. 1. Effect of 12 and 24 h of PCB-95 on RIPK1, RIPK3, MLKL protein expression and caspase-8 mRNA and protein expression. (A-D) Western blots of RIPK1, RIPK3, MLKL,
Caspase-8 in cortical neurons treated for 12 and 24 h with PCB-95 (8 mM). Bars represent the mean ± S.E.M. obtained from three independent experiments. Asterisk symbols
on columns indicate differences between Control (CTL) and PCB-95 treatment. *p  0.05, **p  0.01, ***p  0.001 (one-way ANOVA with Tukey’s post hoc test). (E) qRT-PCR of
caspase-8 in cortical neurons treated for 12 and 24 h with PCB-95 (8 mM). Graphs show quantification of ratio of caspase-8 to HPRT. Bars represent mean ± S.E.M. obtained
from three independent experiments. Asterisk symbols on columns indicate differences between Control (CTL) and PCB-95 treatment. *p  0.05 (one-way ANOVA with
Tukey’s post hoc test). (F) Representative Western blot showing immunoprecipitation between MLKL and RIPK1, and between MLKL and RIPK3 after 24 h of 8 mM PCB-95
treatment. IgG was used as a negative control.
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promoter activity in neurons transfected with pGL3-RIPK1, pGL3-
RIPK3 and pGL3-MLKL strongly increased after PCB-95 treatment,whereas co-transfection of a plasmid overexpressing CREB coun-
teracted these PCB-95-dependent increases (Fig. 7B, E, H). In addi-
tion, transfection of neurons with constructs carrying mutated
Fig. 2. Effect of Necrostatin-1 and siRIPK1, siRIPK3 and siMLKL on PCB-95-induced neuronal death. (A) LDH release in neurons pre-treated for 2 h with Nec-1 at 1, 5, 10 and
20 mM and with PCB-95.Asterisk symbols on columns indicate the significance compared with CTL and asterisk symbols on brackets indicate differences between PCB-95 and
PCB-95 + Nec-1 10 and 20 mM. *p  0.05, ***p  0.001 (one-way ANOVA with Tukey’s post hoc test).(B-D) Western blots of RIPK1, RIPK3, MLKL in neurons transfected with
siRIPK1, siRIPK3, siMLKL or siCTL. Bars represent the mean ± S.E.M. obtained from three independent experiments.*p  0.05, ***p  0.001 vs siCTL (unpaired t test). (E) LDH
release in neurons transfected with siCTL, siRIPK1, siRIPK3 and siMLKL and treated with PCB-95. Asterisk symbols on columns indicate differences between siCTL and PCB-95
+ siCTL; asterisk symbols on brackets indicate differences between siCTL + PCB-95 and PCB-95 with siRIPK1, siRIPK3, siMLKL. ***p  0.001 (one-way ANOVA with Tukey’s post
hoc test).
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pGL3-MLKL-CREmut) resulted in a significant increase in promoter
activity compared to cells transfected with wild type constructs
(pGL3-RIPK1, pGL3-RIPK3 and pGL3-MLKL; Fig. 7B, E, H).To validate that CREB binds in a sequence-specific manner to
RIPK1, RIPK3 and MLKL promoter sequences, SH-SY5Y with or
without PCB-95 treatment were transfected with pGL3-RIPK1,
pGL3-RIPK3, pGL3-MLKL, or with pGL3-RIPK1-CREmut, pGL3-
Fig. 3. Effect of siREST on RIPK1, RIPK3, MLKL and caspase-8 gene and protein expression in PCB-95-treated neurons. (A–D) qRT-PCR of RIPK1, RIPK3, MLKL and caspase-8 in
cortical neurons treated with 8 mM of PCB-95 for 24 h and transfected with siCTL or siREST. Graphs show quantification of ratio of RIPK1, RIPK3, MLKL and Caspase-8 to HPRT.
Bars represent mean ± S.E.M. obtained from three independent experiments. (E–H) Western blotting of RIPK1, RIPK3, MLKL and Caspase-8 in neurons treated with 8 mM of
PCB-95 for 24 h and transfected with siCTL or siREST. Asterisk symbols on columns indicate differences between siCTL and siCTL + PCB-95. Asterisk symbols on brackets
indicate differences between siCTL + PCB-95 and siREST + PCB-95. *p  0.05, **p  0.01, ***p  0.001 (one-way ANOVA with Tukey’s post hoc test).
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treated with 8 mM PCB-95 for 24 h had significantly reduced CREB
protein expression (data not shown). Moreover, PCB-95 treatment
reduced CREB binding to RIPK1, RIPK3 and MLKL exogenous pro-
moter sequences, whereas transfection of vectors containing a
mutation in the CRE sites reverted this effect. These results suggest
that PCB-95 increased RIPK1, RIPK3 and MLKL gene transcription
via CREB down-regulation (Fig. 7C, F, I).
4. Discussion
This study demonstrated that neuronal cell death induced by
PCB-95 involves activation of the necroptotic pathway. Interest-
ingly, we found that PCB-95 exposure modifies the expression of
genes and proteins that are reported to be important for necropto-
sis. PCB-95 treatment caused an increase in RIPK1, RIPK3 and MLKL
gene and protein expression, as well as increased amounts of pro-
tein interactions, in parallel with a reduction in the expression of
the known necroptosis regulator, caspase-8 [16]. Furthermore,
treatment with the RIPK1 inhibitor Nec-1 or transfection with siR-
NAs against RIPK1, RIPK3 and MLKL reduced PCB-95 neurotoxicity.
PCB-95-dependent changes in RIPK1, RIPK3, MLKL and caspase-8
expression likely occurred through up-regulation of the transcrip-
tional repressor REST, which was previously shown to be involvedin PCB-induced neuronal death [11,12,14,15]. Mechanistically, we
found that REST binding to an RE1 site in the rat caspase-8 pro-
moter, Casp8-RE1, down-regulated caspase-8 expression, whereas
reductions in CREB expression and its consequent binding to CRE
sites on RIPK1, RIPK3 and MLKL rat gene promoter sequences
increased expression of these genes. To our knowledge, this report
is the first to show that in neurons: (1) caspase-8 is a REST target
gene, (2) RIPK1, RIPK3 and MLKL are CREB target genes, and (3)
PCB-95 induced cell death by a necroptosis mechanism. The
casp-8-RE1 site present in the caspase-8 gene is located on the for-
ward DNA strand, specifically between nucleotides 1153 to
1134 from the TSS. REST binding to the Casp8-RE1 site is selec-
tive, as revealed by ChIP experiments. In fact, site directed mutage-
nesis of the Casp8-RE1 sequence in neurons completely abolished
PCB-95-induced reductions in caspase-8 transcription due to a
reduction in REST binding to its promoter sequence, as revealed
by ChIP assay with a REST antibody in SH-SY5Y cells transiently
transfected with pGL3-casp8 or pGL3-casp8-RE1-mut. Further-
more, PCB-95-induced REST up-regulation diminished caspase-8
protein expression in neurons. These results are consistent with
previous work showing that transfection with the vector
RESTVP16, in which the REST/NRSF repressor domains were
replaced with the activation domain of viral protein (VP16),
increased caspase-8 activity.
Fig. 4. REST represses caspase-8 rat gene by direct binding to an RE1 site on its promoter region. (A) JASPAR matrix representation (MA0138.1) of the consensus REST binding
site on rat caspase-8 gene (casp8-RE1). casp8-RE1 sequence is represented in IUPAC code. (B) Partial sequence of the genomic caspase-8 region upstream of the exon-1
containing the underlined predicted REST binding site. (C) ChIP with anti-REST of the region containing the RE1 binding site on the caspase-8 gene promoter in PCB-95-
treated neurons (8 lM/24 h). Bars represent the mean ± S.E.M. obtained from three independent experiments. *p  0.05 vs CTL (unpaired t-test). (D) Luciferase assay in
neurons under the following experimental conditions: (1) pGL3basic, (2) pGL3-casp8, (3) pGL3-casp8 + PCB-95, (4) pGL3-casp8 + siCTL + PCB-95, (5) pGL3-casp8 + siREST
+ PCB-95, (6) pGL3-casp8-RE1mut + PCB-95. Bars represent the mean ± S.E.M. obtained from three independent experiments. Asterisk symbols on columns indicate
differences vs pGL3-casp8; asterisk symbols on brackets indicate differences between pGL3-casp8 + PCB-95 and pGL3-casp8 + siREST + PCB-95 or pGL3-casp8-RE1mut + PCB-
95. ***p  0.001 (one-way ANOVA with Tukey’s post hoc test). (E) Chromatin was immunoprecipitated with anti-REST from SH-SY5Y cells transiently transfected with pGL3-
casp8 and pGL3-casp8-RE1mut and exposed to PCB-95. Asterisk symbols on columns indicate differences vs pGL3-casp8; asterisk symbols on brackets indicate differences vs
pGL3-casp8 + PCB-95. *p  0.05, **p  0.01 (one-way ANOVA with Tukey’s post hoc test).
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MLKL gene and protein expression were reversed by transfection
of silencing for REST, thereby suggesting that by up-regulating
REST expression PCB-95 treatment modulates transcription of
necroptosis pathway genes. Bioinformatics analysis with the Jaspar
database showed no REST binding, but did identify CREB binding
sites, which may be important for down-regulating expression of
these genes. Through REST, PCB-95 treatment induced reduction
in levels of CREB and consequent increases in RIPK1, RIPK3 and
MLKL expression. Moreover, REST silencing reversed PCB-induced
reductions in CREB levels, whereas CREB overexpression in PCB-
95-treated neurons blocked RIPK1, RIPK3 and MLKL increases.
Together these results suggested that: (1) REST is a CREB repressor
and (2) CREB is a transcriptional suppressor of RIPK1, RIPK3 and
MLKL genes. Notably, in previous studies it has been showed that
CREB positively regulates REST expression in small-cell lung cancer
[33]. However, the finding that REST silencing reversed PCB-95-
mediated reduction in CREB seems to suggest that in our experi-
mental model REST is a regulator of CREB expression. Indeed, we
found one CRE site in rat RIPK1, RIPK3 and MLKL genes (RIPK1-
CRE, RIPK3-CRE and MLKL-CRE) located at 792/771,
1013/992 and 1081/1060, respectively, from the TSS, which
may act as molecular determinants involved in CREB-inducedRIPK1, RIPK3 and MLKL regulation. Importantly, ChIP experiments
revealed that PCB-95 induced a reduction in CREB binding to the
RIPK1-CRE, RIPK3-CRE and MLKL-CRE sites, and this binding was
sequence-specific as shown by luciferase experiments in neurons
transfected with constructs containing the relevant CRE sites. To
our knowledge, this is the first characterization of the relationship
between PCB-95 exposure and CREB expression.
Together our results indicate that CREB-dependent reduction
in RIPK1, RIPK3 and MLKL expression is induced by PCB-95
through increases in REST. Although CREB can act as a transcrip-
tional gene activator [33] or transcriptional gene repressor [34],
in this model it acts as a repressor of RIPK1, RIPK3 and MLKL
genes. These results are consistent with a previous study demon-
strating that CREB negatively regulates insulin-like growth factor
2 receptor gene expression in cardiomyoblasts [35]. Moreover,
our findings support the well-known neuroprotective role of CREB
in neurological disorders associated with cell death, such as
stroke and epilepsy [36]. From our findings that the CREB rat pro-
moter sequence lacks an RE1 binding site and that neither PCB-95
treatment nor siRNA mediated knockdown of REST expression
affected CREB gene expression, we hypothesize that PCB-95-
mediated effects are not due to the binding of REST to the CREB
rat promoter sequence.
Fig. 5. Identification of putative CREB binding sites on RIPK1, RIPK3 and MLKL rat genes. (A) JASPAR matrix representation (MA0018.2) of the consensus CREB binding site on
rat RIPK1 (RIPK1-CRE), RIPK3 (RIPK3-CRE) and MLKL (MLKL-CRE) genes. RIPK1-CRE site, RIPK3-CRE site and MLKL-CRE site are represented in IUPAC code. (B–D) Partial
sequences of the genomic RIPK1, RIPK3 and MLKL regions upstream of the exon-1 containing the underlined predicted CREB binding sites.
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Fig. 6. REST by down-regulating CREB increases RIPK1, RIPK3, MLKL mRNA and protein expression in neurons treated with PCB-95. (A, B) qRT-PCR and Western blot analysis
of CREB in cortical neurons treated with 8 mM of PCB-95 for 24 h and transfected with siCTL or siREST. Bars represent mean ± S.E.M. obtained from three independent
experiments. Asterisk symbols on columns indicate differences between siCTL and siCTL + PCB-95. Asterisk symbols on brackets indicate differences between siCTL + PCB-95
and siREST + PCB-95. *p  0.05 and **p  0.01 (one-way ANOVA with Tukey’s post hoc test). (C) Western blot of CREB in neurons transfected with an empty vector (Mock) or
with a plasmid overexpressing CREB. Bars represent the mean ± S.E.M. obtained from three independent experiments. Asterisk symbols indicate differences between Mock
and CREB. **p  0.01 (unpaired t-test). (D–I) qRT-PCR and Western blot of RIPK1, RIPK3, MLKL in cells transfected with Mock or CREB and treated with PCB-95. Bars represent
the mean ± S.E.M. obtained from three independent experiments. Asterisk symbols on columns indicate differences between Mock and Mock + PCB-95. Asterisk symbols on
brackets indicate differences between Mock + PCB-95 and CREB + PCB-95. *p  0.05, **p  0.01, ***p  0.001 (one-way ANOVA with Tukey’s post hoc test).
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Fig. 7. CREB represses RIPK1, RIPK3 and MLKL genes by direct binding to a CRE site on their promoter regions. (A, D, G) ChIP with anti-CREB of the regions containing the CREB
binding sites on the RIPK1, RIPK3 and MLKL gene promoters in PCB-95-treated neurons (8 lM/24 h). Bars represent the mean ± S.E.M. obtained from three independent
experiments. *p  0.05 vs CTL (unpaired t-test). (B) Luciferase assay in cortical neurons under the following experimental conditions: (1) pGL3-basic, (2) pGL3-RIPK1, (3)
pGL3-RIPK1 + PCB-95, (4) pGL3-RIPK1 + Mock + PCB-95, (5) pGL3-RIPK1 + CREB + PCB-95, (6) pGL3-RIPK1-CREmut constructs. Bars represent the mean ± S.E.M. obtained from
three independent experiments. Asterisk symbols on columns indicate differences vs pGL3-RIPK1. Asterisk symbols on brackets indicate differences between pGL3-RIPK1
+ PCB-95 and pGL3-RIPK1 + CREB + PCB-95. Hashtag symbols on brackets indicate differences between pGL3-RIPK1 + CREB + PCB-95 and pGL3-RIPK1-CREmut. **p  0.01 and
***p  0.001, ###p  0.001 (one-way ANOVA with Tukey’s post hoc test). (E) Luciferase assay in cortical neurons under the following experimental conditions: (1) pGL3-basic,
(2) pGL3-RIPK3, (3) pGL3-RIPK3 + PCB-95, (4) pGL3-RIPK3 + Mock + PCB-95, (5) pGL3-RIPK3 + CREB + PCB-95,(6) pGL3-RIPK3-CREmut constructs. Bars represent the
mean ± S.E.M. obtained from three independent experiments. Asterisk symbols on columns indicate differences vs pGL3-RIPK3. Asterisk symbols on brackets indicate
differences between pGL3-RIPK3 + PCB-95 and pGL3-RIPK3 + CREB + PCB-95. Hashtag symbols on brackets indicate differences between pGL3-RIPK3 + CREB + PCB-95 and
pGL3-RIPK3-CREmut. ***p  0.001, ###p  0.001 (one-way ANOVA with Tukey’s post hoc test). (H) Luciferase assay in cortical neurons under the following experimental
conditions: (1) pGL3-basic, (2) pGL3-MLKL, (3) pGL3-MLKL + PCB-95, (4) pGL3-MLKL + Mock + PCB-95, (5) pGL3-MLKL + CREB + PCB-95, (6) pGL3-MLKL-CREmut constructs.
Bars represent the mean ± S.E.M. obtained from three independent experiments. Asterisk symbols on columns indicate differences vs pGL3-MLKL. Asterisk symbols on
brackets indicate differences between pGL3-MLKL + PCB-95 and pGL3-MLKL + CREB + PCB-95. Hashtag symbols on brackets indicate differences between pGL3-MLKL + CREB
+ PCB-95 and pGL3-MLKL-CREmut. ***p  0.001, ###p  0.001 (one-way ANOVA with Tukey’s post hoc test). (C, F, I) Chromatin was immunoprecipitated with CREB antibody
from SH-SY5Y cells transiently transfected with: (C) pGL3-RIPK1 and pGL3-RIPK1-CREmut, (F) pGL3-RIPK3 and pGL3-RIPK3-CREmut, (I) pGL3-MLKL and pGL3-MLKL-CREmut
and therefore exposed to PCB-95 (8 lM/24 h). Bars represent the mean ± S.E.M. obtained from three independent experiments. Asterisk symbols on columns indicate
differences vs pGL3-RIPK1 (C), pGL3-RIPK3 (F) and pGL3-MLKL (I). Asterisk symbols on brackets indicate differences vs pGL3-RIPK1 + PCB-95 (C), pGL3-RIPK3 + PCB-95 (F) or
pGL3-MLKL + PCB-95 (I). **p  0.01, ***p  0.001 (one-way ANOVA with Tukey’s post hoc test).
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can induce necroptosis in neurons and is in accordance with our
previous study demonstrating that neurons exposed to 8 mM
PCB-95 for 24 h showed no caspase-3 activation, that is typical of
apoptosis, and supports the involvement of programmed necrosis
[11].
Necroptosis is a relevant mechanism of cell death in in vitro and
in vivo models of neurological diseases such as ALS, Huntington’s
disease, Parkinson’s disease [37], stroke [16] and MS [18]. Notably,
in models of all these diseases, cell survival was increased and
necroptosis was reduced by treatment with the RIPK1-specific
inhibitor Nec-1. Here we also observed that Nec-1 dose-
dependently reduced PCB-95 induced neuronal death, with 10
ΜM having the maximum inhibitor effect on PCB-95-induced neu-
rotoxicity. Additionally, we found that RIPK1, RIPK3 and MLKLknockdown reverted the neurotoxic effect of PCB-95, suggesting
involvement of these proteins in neuronal necroptosis, which is
similar to previous findings in other cell systems such as the kid-
ney, where necroptosis is a major mechanism of proximal tubular
cell death in cisplatin-induced nephrotoxic acute kidney injury
[38]. Furthermore, in our system we cannot exclude the possibility
that other concentrations or treatment times for PCB-95 could acti-
vate other types of cell death such as apoptosis or autophagy. In
addition, we did not test the effect of the MLKL inhibitor necrosul-
fonamide on PCB-95-induced cell death in primary rat cortical neu-
rons because this drug is specific for the human isoform [39].
PCB-95 exposure has also been identified as a probable environ-
mental risk factor for neurodevelopmental disorders such as aut-
ism. A recent study by Dunaway et al. analyzed human brain
tissue complemented with experimental neuronal cell culture
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duplications and PCB-95 exposure on genes that have roles in neu-
ronal synapses, transcriptional regulation, and signal transduction
pathways [40].
Collectively, our results indicate that necroptotic-dependent
cell death induced by PCB-95 treatment in rat cortical neurons
depends on increases in REST expression that elicit: (1) reduced
caspase-8 gene and protein expression directly induced by REST
binding to a specific rE-1 site present in the caspase-8 promoter
sequence and (2) increased RIPK1, RIPK3, and MLKL gene and pro-
tein expression via a reduction in CREB binding to putative pro-
moter sequences. Furthermore, the necroptotic death pathway
mediated by PCB-95 exposure could underlie the damaging effect
of REST that is associated with stroke [16,22,41–43]. In fact, both
REST and activation of necroptosis are associated with phys-
iopathological mechanisms of brain ischemia. Drugs that inhibit
necroptosis could be a new therapeutic strategy for many neuro-
logical diseases associated with PCB exposure or where the tran-
scription factor REST is overexpressed.
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